Biography
Dr. Quincy Quick is an Associate Professor of Biology at Tennessee State University and was the E.E. Just Endowed Professor of Biology at Grambling State University. Dr. Quick’s academic appointments were preceded by postdoctoral studies at UMass Medical School, where he studied the role of p53 family members, p63 and p73, in brain tumor development. Additionally, he conducted postdoctoral studies as a Massey Cancer Center postdoctoral fellow at the Virginia Commonwealth University Medical Center, where he investigated radiation induced-senescence arrest and radiation-sensitization of brain tumors, as well as a brief postdoctoral stint at the University of Toronto (Sunnybrooke Hospital), where he studied the effects of radiation on the central nervous system. Currently, Dr. Quick is studying a novel cytoskeletal crosslinking protein as a target in glioblastomas with therapeutic applicability to precision medicine approaches for the treatment of this disease that is supported by the National Institutes of Health (USA). Dr. Quick is also a standing reviewer for several cancer journals and is a participant on cancer grant review panels.Prof. Salvatore Ulisse received a Doctoral degree with honor in Biological Sciences at the University of Rome “Sapienza” in 1985. From 1987 to 1989, he worked in quality of Adjunct Scientist in the laboratory of the National Institute of Child and Human Development, National Institute of Health, Bethesda (MD), USA. In 1990, he joined as Guest Researcher in the laboratory of National Institute of Dental Research, National Institutes of Health, Bethesda (MD), USA. In 1991, he become a Researcher at the University of L’Aquila (L’Aquila, Italy). From 1993 to 1995, he joined as Visiting Scientist to the Laboratory of Developmental Biochemistry, National Institute for Medical Research, Medical Research Council, London UK. From 2003 to date, he has been spending short periods of time as “Invitè Professor” at the University of Rennes 1 (Rennes, France). In 2006, he become an Associate Professor at the “Sapienza” University of Rome. The scientific activity of Prof. Salvatore Ulisse is documented by more than 150 publications on peer-reviewed scientific journals and book chapters. Over the last decade, the main research activity of Prof. Ulisse has been focused on the physiopathology of the male and female reproductive axes, on the mechanism of action of thyroid hormones and on the molecular mechanisms involved in the progression of endocrine neoplasms.Dr. Lin Tian is currently a post-doctoral scholar at Memorial Sloan Kettering Cancer Center (MSKCC) in Dr. Joan Massagué lab. His research focuses on uncovering the mechanisms of innate immunity in metastasis. Prior to joining MSKCC, Dr. Lin Tian received his Ph.D. degree from Biochemistry and Molecular Biology Program at Baylor College of Medicine in 2017. Before the graduate study, he received a B.S. in Biotechnology and Bioengineering from Shanghai Jiao Tong University in 2011.Dr. Robert Memba is Associate Professor of Surgery at Rovira i Virgily University in Tarragona, Spain. He is an hepato-pancreato-biliary surgeon with an interest in hepatobiliary and pancreatic diseases, particularly liver and pancreatic malignancies. He is currently the head of the hepato-pancreato-biliary unit of Joan XXIII University Hospital in Tarragona, Spain. He is also chairman of a non-governmental organization and executive board member of a hospital in Barcelona. His research field is mainly pancreatic cancer and pancreatitis. He has several publications and book chapters on those topics and has been a speaker in various national and international conferences. Prior to joining Rovira i Virgili University, he worked as lecturer in surgery at Trinity College of Dublin and fellow researcher at the Centre for Pancreatobiliary diseases based in Tallaght Hospital, Dublin.Dr. Amal Saad-Hussein is a Professor of Environmental Health & Preventive Medicine, National Research Center, Egypt. She is interested about environmental carcinogens, prediction, early diagnosis and prevention. Her publications in the field of Climate Change health vulnerability and adaptation, Environmental Toxicology, Environmental Health Impact Assessment and Molecular Epidemiology, Prediction of health problems related to environmental pollutions, Evaluation of preventive and therapeutic management of health problems related to environmental pollutions, and design strategies for prevention and control, and Environmental Health Education and Public Awareness.Dr. Marco De Martino graduated in Medical Biotechnology in 2013 at the University of Naples "Federico II", carrying out his thesis at the Department of Molecular Medicine and Medical Biotechnology, under the supervision of Prof. Alfredo Fusco. In 2017, he discussed his Ph.D thesis and got Ph.D in Molecular Medicine at the Department of Molecular Medicine and Medical Biotechnology University of Naples "Federico II". From 2017 Dr. De Martino is Post-Doc Researcher at the CNR-IEOS, Italy. The research project led by Dr. De Martino aims to achieve the following objectives: a) identification of the HMGA targets: isolation and characterization of microRNAs and genes regulated by the HMGA proteins. b) role of HMGA proteins in cancer progression: identification and characterization of molecular interactors. c) analysis of the "competitive endogenous RNAs" (ceRNAs) for HMGA1: the HMGA1 pseudogenes (HMGA1P6 and HMGA1P7).Dr. Mohamed Rahouma is currently Research Associate in Department of Cardiothoracic Surgery, Weill Cornell Medicine/New York Presbyterian Hospital, New York, USA and Assistant Lecturer in Surgical Oncology Department, NCI, Cairo University, Egypt. He is especially dedicated to thoracic surgical oncology in addition to his gained experience in minimally invasive cardiothoracic surgery. He got a deep working experience in statistics and meta-analysis in particular and successfully published over 25 meta-analyses till now working from his both affiliations (NCI/Egypt and Cornell/USA). He received his medical degree from Cairo University in 2007, finished his surgical oncology residency in 2012 and earned Master in Surgical Oncology (MSc) in 2013 from NCI/Cairo University in addition to membership of Intercollegiate Royal College of Surgeons (Intercollegiate MRCS) in 2013. He promoted to Assistant Lecturer and joined faculty staff of NCI/Cairo University in 2013 and he finished 2 years of fellowship in surgical oncology with particular emphasis on thoracic malignancies. Since 2015, he is working as a research fellow on his clinical Ph.D in minimally invasive esophageal cancer in a joint supervision mission between NCI/Egypt and Cornell/USA. At 2018, he was promoted from research fellow to be research associate in Cardiothoracic Surgery, WCM. His researches focus on investigation of the best treatment modalities for thoracic cancer patients that included but not limited to lung, esophageal cancer, thymoma, mesothelioma, hyperthermic intra-pleural/intra-peritoneal chemotherapy and immunotherapy in addition to his work on cardiac surgery and meta-analysis as well. He has published almost 150 articles, and be an editor in 5 journals and reviewers in 8 journals with particular interest in Minimally Invasive Cardiothoracic Surgery (including tumors of lung, thymus, esophagus in addition to minimally invasive coronary artery bypass graft and mitral surgery). He is also interested in conducting meta-analyses in different Cardiothoracic Surgery and Oncology fields in addition to grants writing. Currently he is editing a book about Thoracic Malignancies: A Deep Insight in addition to many ongoing meta-analyses and meta-analysis of prior meta-analyses. Articles Published in CPQ Cancer is 50 Gene Panel Testing in Non-Small Cell Lung Cancer and Options for Targeted Therapy, Anticoagulation in Surgery, Thoracic Malignancies: Insights into Different Therapeutic and Technical Options, TP53 Mutations and its Consequences: Insight into Leukemia and Lymphoma Cases, Infantile Hepatic Hemangioendothelioma, A Review of Literature, Virtosome: Is it the Answer to Liquid Biopsy Dilemma?Dr. Fariba Goudarzi, 31 years old from Iran has finished B.S. program in the department of biological science at the University of Tabriz in General Biology, GPA: 15.06/20 (3.0/4.0), July 2009. She finished her M.S. program in the University of mohaghegh ardabili GPA: 18.75/20 (3.93/4.0), February 2013. She graduated in Molecular and Cellular Biology and researched about the Drug Delivery and cancer researches (Effect of Nisin on Cancer Cell Lines and Bacterial Strain). Her publications include In Vitro Characterization and Evaluation of the Cytotoxicity Effects of Nisin and Nisin-Loaded PLA-PEG-PLA Nanoparticles on Gastrointestinal (AGS and KYSE-30), Hepatic (HepG2) and Blood (K562) Cancer Cell Lines. AAPS PharmSciTech, DOI: 10.1208/s12249-018-0969-4, (2018), Assessment of Stemness in mesenchymal cells of human umbilical cord warton’s-jelly during differentiation to germ-like cells. New Cellular and Molecular Biotechnology Journal, (2016). A comparison study of the Antibacterial Effects of Nisin and Nisin-loaded on PLA-PEG-PLA Nanoparticles on Staphylococcus Aureus and Bacillus Cereus Bacterial Strains. Probiotics and Antimicrobial Proteins, (under review) and Investigation on Anticancer Activity and Apoptosis Induction of Brevinin-2R and Brevinin-2R-Loaded PLA-PEG-PLA Nanoparticle and Strong Cell Cycle Arrest in AGS, HepG2 and KYSE-30 Cell Lines. Journal of Pharmaceutical Innovation, (under review). Dr. Peter Allan Sandwall II, Ph.D. is a board certified medical physicist and the founder and managing partner of Precision Physics, Inc., an international medical physics and dosimetry consulting firm. He currently serves as medical physicist for OhioHealth, Mansfield Hospital, where he is engaged in multi-institutional and externally funded research projects with emphasis on computer vision, luminescence, and radiation dosimetry. Prior to joining OhioHealth, he was Chief Medical Physicist for US Oncology and Senior Medical Physicist with Vantage Oncology.
Dr. Sandwall has served as an adjunct professor in the University of Cincinnati’s Department of Advanced Medical Imaging Technology and as a consultant for Schneider & Wuest, Inc. He is an authorized medical physicist with the U.S. Nuclear Regulatory Commission and a diplomate of the American Board of Radiology in therapeutic medical physics. With a doctorate in nuclear engineering and master of science in health physics from the University of Cincinnati. Dr. Sandwall holds leadership roles in the Health Physics Society, the American Association of Physicists in Medicine, and EmpowerRT a social enterprise University startup, whose mission is to help people in developing countries improve radiotherapy. One of his passions is contributing time as a volunteer for Radiating Hope, helping to coordinate medical equipment donations to Latin American countries such as Honduras and Guatemala.Dr. Mohd Iqbal Yatoo completed his Masters and Doctorate Degree in Veterinary Medicine from Indian Veterinary Research Institute (India) and is presently serving as Assistant Professor in Division of Veterinary Clinical Complex, Faculty of Veterinary Sciences and Animal Husbandry, Shuhama, Srinagar, India (SKUAST-K). He has published research in journals of National and International repute and has to his credit 12 Reviews, 8 International and more than 30 National papers besides a book, few popular articles, case reports and extension literatures. His research work includes in-vitro and in-vivo exploration of medicinal plant extracts as antioxidants, anti-inflammatory, anti-cancer and immunomodulatory agents in diseases of recent importance like diabetes and cancer. Besides he is working on mycoplasmosis in goats and has been awarded a project in this field. He is currently guiding students for MVSc and PhD degrees. Other assignments include teaching, research and extension activities of the University.Dr. Chrow Khurshid is a doctor in biochemistry and cancer drug development field, worked as researcher at the University of Manchester/ chemistry school, Manchester institute of biotechnology, and University of Salford Manchester where she has completed her Ph.D. on biochemistry and developing drug to treat triple negative breast cancer. Her master was in biochemistry field, she studied the effects of free radicals on mammalian organs using in vivo model study. Her research interests lie in the area of cancer research, drug design and discovery, natural products and biochemistry sciences. She has collaborated actively with researchers in several other disciplines such as glycomic group from university of California San Diego, proteomics groups at university of Manchester and university of Liverpool and biomedical researches such as parasitology at university of Salford Manchester. Chrow has attended many conference and workshop programs on advance biotechnologies such as analytical techniques including HPLC, MS, and NMR. In addition to flow cytometry, cell and tissue culture, and several bioinformatics and computational biology. Chrow has many publications in scientific journals and conferences which are available online in open access journals.Dr. Marveh Rahmati is currently an Assistant professor at Cancer Biology Research Center, Tehran University of Medical Sciences. She obtained her Ph.D in Medical Biotechnology from Tabriz University of Medical Sciences (Iran) and spent a 6-month course as a research fellow at National University of Ireland, Galway. She is actively involved in epidemiologic and epigenetic projects on Iran cancer patients. She published some peer-reviewed papers and received several national awards including, “young scientist awards” from Iranian Society of Microbiology in 2009 as well as “the best researcher awards” and “top students award” from Alzahra University in 2008. Dr. Rahmati is also editor of the book entitled “signaling pathways controlling cell fate: apoptosis, autophagy and ER stress. She is a member of several scientific organizations and acts as a reviewer for different journals.Dr. Zhang is a postdoctoral fellow studying the molecular mechanisms for dysregulated gene transcription in breast cancer at The Rockefeller University. He received his PhD in cancer biology from MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences. He aims to elucidate mechanisms by which estrogen receptor interactions with cofactors and the Mediator, effect the development of breast cancer and transcription of ER target genes. He recently showed a critical role of the reversible m6A mRNA methylation in tumor development by demonstrating that ALKBH5, an aberrantly upregulated m6A demethylase in glioblastoma stem-like cells (GSCs), demethylates the nascent transcripts of FOXM1 to promote GSC tumorigenesis.Dr. Sweta Mathur is currently pursuing Residency in Dental Public Health at the Case Western Reserve University, Cleveland, OH. She was recently awarded PhD in Dental Public Health from the University of Glasgow, Glasgow, UK (June 2019). Her PhD thesis involved a systematic overview to establish best practice for risk assessment and prevention of major oral cancer risk factors (tobacco and alcohol), and qualitative interviews with dental professionals and patients attending General Dental Practices to investigate the feasibility of translating best practice evidence to a pilot to support professionals in daily preventive care. She also has a Masters of Public Health (MPH) from the University of Glasgow, UK, and a Bachelor of Dental Surgery (BDS) from India. Her interests include analyzing the oral and general health of the community and to formulate and maintain healthcare principles and advancements.Dr. Susanna Akiki is a Consultant Clinical Scientist specialising in molecular pathology with a particular interest in myeloid malignancies. She completed her PhD in haematology at University College London in 1995 then moved into cancer diagnostics at the Royal London Hospital. In 2002 Dr Akiki joined the West Midlands Genetics Laboratory as Head of Haemato Oncology Genetics and later as Deputy Head of Cancer Services. In 2015 Dr Akiki was appointed as Consultant Clinical Scientist for cancer genomics at Hamad Medical Corporation to contribute to the development of services aligned to the 2030 Qatar National Vision for a world class healthcare system.Dr. Saranya Ramalingam Singaravelu is a doctorate in Biotechnology did doctoral research at Karpagam University, India. Her research is in the area of occupational health and toxicity. Specifically, the research in her group involves: (i) Biomonitoring of human genotoxicity induced by diverse occupational exposures and (ii) Evaluation of DNA damage in the buccal mucosa of tobacco chewers. She has authored more than 15 refereed journal publications. Currently she teaches Immunology, IPR, Biodiversity,Biosafety. Her core research is in occupational genotoxicity.Dr. Raj Sewduth was born in Mauritius. After a master in genetics at King’s College, UK, he obtained his PhD in physiopathology at INSERM U1034, Bordeaux, France. For his postdoctoral studies, he joined the Department of Oncology at KU Leuven / VIB cancer in Belgium. His scientific interests have been to understand the molecular basis of human disease. He worked in the past on characterization of mutations associated to dystrophin in patients with rare neurological diseases, then on the role of ubiquitination in Wnt signaling, in development and pathologies such as stroke. His current project is to look at the role of oxidation and ubiquitination in breast and brain cancer, using complex genetic models spontaneously giving rise to cancer to study the of ubiquitin hydrolase and ligases in oncogenesis. The idea is to assess how oxidation and ubiquitination of oncogenes affect stability, trafficking and signal transduction, leading to pathological conditions. Finally, he has a strong interest in innovative technologies such as MRI, Micro CT for imaging, as well as proteomics strategies to identify targets that could be druggable.Dr. Parvin Mehdipour focal interest includes Cancer Genetics/Tumor Biology. Her academic/research life was based on the multi-disciplinary insights during 35 years in Tehran University of Medical Sciences. Her inspirations included the cascades of puzzles by considering the molecular/ functional targets to pave the ways for bridging Cell Biology and Cancer Genetics to the clinics. She has traced the junctions and cross dialogues between the cancer cells as the roots to unmask the cancer facts. Her Scientific and academic links with overseas Universities include 1) Institute of Human Genetics- in Erlangen-Nuerenberg, & Bonn, & Dresden, and Manchester University. 2) Institute of Medical Genetics of Humboldt University/Charite in berlin. 3) German Cancer Research Centre (Deutsche Krebs Forschung zentrum:DKFZ) in Heidelberg, and University of Romania. She started her PhD thesis by initiating a research project on Human leukaemias at Department of Genetics, Royal Liverpool hospital, University of Liverpool. Since then (1982), she has initiated the routine application of Cytogenetic study in patients with Haematopoietic disorders including the candidates for bone marrow transplantations in Iran. Besides, the exploration on of solid tumors was her top concern to prove couple of evolutionary hypotheses in different cancers to innovate cancer-biomarkers. Early detection of neoplasms has occupied her life, since 1998, by focusing on 1) Circulating Tumor Cells. 2) Scenarios of tumor migration. 3) Modeling of cancer metastasis. 4)Personalized cancer- Diagnosis/Prediction/Prognosis/Prevention, as the quadrant-requirements in clinical managements including personalized therapy. Her complementary curiosities include writing, painting and nutrigenomics. She edited 4 books with Springer.Dr. Othman Alfleesy is currently working as associate Professor in department of forensic medicine and pathology at faculty of medicine, Aden University-South Yemen. He has completed his MSc in Forensic Medicine in college of higher studies in Jordan (1989). He is a member in an international association of forensic medicine. Dr. Alfleesy had participated and contributed to numerous International conferences (has presented papers or posters). He has attended in a number of national and International conferences & workshops (including workshops of WHO). He also has published a number of valuable researches in a number of international scientific Journals, (in which he forwarded (for the first time) solutions for, 1. sudden infant death syndrome (Alfleesy Hypothesis). 2. He had explained Bangungut and put a solution for this delimma. 3. Also he discovered a wrong theory of Zuckerman for oogenesis (1951). Alfleesy discovered the wrong theory of Calvin Bridge (1909) for nondisjunction extrachromosome 21 and Down Syndrome) and put a new scientific suggestion. Alfleesy has announced an appeal to all mothers in the world that they are not a responsible for Down Syndrome children as the scientists had claimed for a century. He is an author of two books. The forensic medicine book, which had winned the University award in 2000.And the other book medical ethics. He is also a member in an Editorial Boards in a number of International Journals.Dr. Michael Friedrich, The main field of his research activities is dealing with the vitamin d metabolism in gynaecological malignancies and in breast cancer. Another field he working on is the interaction of DNA-mismatch repair and resistance to chemotherapy in gynaecological malignancies. Further mainpoints are the interstitial brachytherapy for recurrences of cervical cancer, the use of innovative therapies in gynaecological malignancies, the technique of sentinel lymph node in gynaecological malignancies especially in vulvar cancer and the use of intraoperative intraperitoneal chemotherapy (HIPEC) in ovarian cancer.Dr. Ashley S. Plant, MD is currently the Director of Pediatric Neuro-Oncology at Children's Hospital Orange County. She previously worked at Dana Farber Cancer Institute/Boston Children's Hospital where she also completed her hematology/oncology and neuro-oncology fellowship training. She did her pediatric residency at University of California, Los Angeles and her medical school training at Stanford University School of Medicine.Professor Constantine - Gerasimos S. Gennatas received his Medical School Diploma cum laude in 1971(University of Athens, Greece). He served as House Officer at the Department of Medicine, Evangelismos Hospital in Athens for six months and from 1972 to 1974 he was a Resident at the Department of Medicine at Mount Sinai Hospital, Chicago. From 1974 to 1976 he worked as Fellow in Oncology at the same Hospital. From 1977 to 1978 he has worked as Attending Physician at the Department of Medicine, Kavala General Hospital in Greece and from 1978 to 1980 as Attending Physician at Metaxas Memorial Cancer Hospital in Piraeus, Greece. In 1980 he obtained his MD degree (Thesis) at the University of Athens. In 1989 he became Assistant Professor and in 1997 Associate Professor of Medical Oncology. In 2011 he was elected Professor of Medical Oncology at the University of Athens. Since 2014 he is Professor Emeritus. From 1980 until 2014 he was Physician-in-charge, Oncology Clinic, 2nd Department of Surgery, University of Athens, Areteion Hospital in Athens. He is Emeritus Member of the American Society of Clinical Oncology (ASCO) and has served as President of the European Association for Cancer Education. He has several publications in English and Greek and has attended more than 400 National and International Meetings.Dr. Mohamed Kamel Kamel Hussein graduated from medical school in 2006, and then he completed a residency in surgical oncology in 2011. He was appointed as a junior faculty member at the surgical oncology department at the National Cancer Institue, Egypt. He came to USA in 2014 where he worked as a research fellow for 3 years. Now he is doing a clinical fellowship at the cardiothoracic surgery department at Weill Cornell Medical College, USA. He has many publications in high-impact journals and have a good experience in statistical analyses of different kinds including meta-analyses.Dr. Sabiha Fatima has been a faculty member since 2011. She completed her Masters and PhD in biochemistry at Aligarh Muslim University, India. Her research interest is in the field of drug and chemical induced toxicology and oxidative stress. Sabiha has supervised many graduate research projects as main and co-supervisor and has already published some of the findings of her research in well reputed international journals. Dr. Mehrdad Payandeh educated in filed of hematology - oncology and bone marrow transplantation in TEHRAN university of medical sciences in Iran. During these 14 years he has Been activated in this filed and during last years he beginning with kermanshah-BMT center in west of Iran. He published more that 150 articles in all of these fileds. Dr. Cuneyt Tetikkurt was born in Istanbul in 1960. He graduated from Istanbul Medical Faculty in 1984. After two years of compulsory service in a goverment hospital he started residency in the Istanbul Medical Faculty Pulmonary Diseases Department of five years. During 1986 he worked as a visiting physcician in the Cleveland Clinic Internal Medicine Department. He began to work in as a consultant physician in 1991 at the Istanbul Medical Faculty Pulmonary Diseases Department and worked there as a specialist and a consultant physician for two years. He became an associated professor at the Pulmonary Disease Department of Istanbul Medical Faculty in 1993. He was appointed as an associated professor at the Cerrahpasa Medical Faculty of Pulmonary Diseases Department in 1999. In 2000, He became a professor at the Cerrahpasa Medical Faculty Pulmonary Diseases Department. Now he work as a lecturer at the same department.Dr. Md Sanaullah Sajib working at Texas Tech University Health Sciences Center as a research assistant. The focus of his research is to understand the basics of tumor metastasis with particular focus on the interaction of cancer cells with endothelial cells during trans-endothelial migration.Dr. Fardous F. El-Senduny is an assistant Professor of Biochemistry and Molecular Biology at Biochemistry Division, Chemistry Department, Faculty of Science at Mansoura University in Egypt. In 2010, she received the MSc in Biochemistry and Molecular Biology from Bremen University, Germany. During her stay in Germany, she received different internships in the field of cancer biology, drug discovery and host-pathogen interaction in Helmholtz institute for Infection Research in Braunschweig. In 2013, she joined the department of Chemistry and Biochemistry in South Dakota State University, Brookings in USA as a research associate for two years. In 2015, she received her PhD in Biochemistry and Molecular Biology from Faculty of Science, Mansoura University, Egypt. In 2017, she visited the Indian Institute of Technology Guwahati (IITG) for two weeks as a part of Indo-Egyptian collaboration funded by Indian Government and Egyptian Government. In 2019, she visited Biotechnology and Biomedicine Centre of the Academy of Sciences and Charles University (BIOCEV), Czech Republic for two months in Cancer Biology lab with Prof. Dr. Jan Brábek.Dr. Raquel Santana da Cruz is a postdoctoral at the Georgetown University Medical Center located in Washington, DC. She is from Sao Paulo, Brazil, where she lived for almost all her life with her family that encourage her to follow her dreams. She is a Biology research scientist with a bright research career, culminating in peer-reviewed journals. She graduated from University of São Paulo, Brazil with a B.S. in Biology. She graduated from University of São Paulo with a Ph.D. in Food Science. During her Ph.D., her research focused on evaluating Breast Cancer programming in early life. Also, she set up the Animal Protocol, in partnership with Dr. De Assis Lab, to study fetal programming of breast cancer with mice, which have been used for new Ph.D. students in her mentor research group. Additionally, she was on several training committees and development programs for research trainees. At Georgetown, she has been working with the effects of paternal nutrition before conception on the susceptibility offspring’s Cancer risk. She is conducting innovative Breast Cancer research and is an expert on how ancestral exposures such as Obesity and other forms of Malnutrition before conception can modulate the risk of Breast Cancer and other Cancer in the next generation. Her main project focused on how Paternal Malnutrition affects not only Breast or Pancreatic Cancer risk but also Tumor Metabolism in offspring, using a Mouse Model. One of the papers derived from this study was published in Breast Cancer Research (Breast Cancer Res. 2018 Aug 30;20(1):99. doi: 10.1186/s13058-018-1034-7). Her long-term research interest involves developing a comprehensive understanding of how Dietary Exposure and Environmental Cues might influence the risk for Breast Cancer development. She has a strong commitment to Cancer prevention research and to improve the life quality of patients.Dr. Winston Wong, Pharm D, is the President of the W-Squared Group. The W-Squared Group is committed to assist small niche healthcare innovators develop their value statement, and then launch their technology in the government and commercial marketplace. He is also the current Editor-In-Chief for the Journal of Clinical Pathways, a journal committed to providing high-quality educational and informational articles as well as presenting original health economic outcomes research data in the clinical pathway arena. He is known for his clinical innovations throughout his 30-year career. Among his accomplishments are participating as a member of the APhA STAT committee first addressing the value of MTM services, implementation of a provider network Pay-for-Quality program in Oncology and Rheumatology, and incorporating MTM services into the overall Medical Management Strategy in a health plan. He earned his Pharm D degree in 1981 from the University of the Pacific in Stockton California, and completed a General Residency at the University of Nebraska Hospital and Clinics in Omaha, Nebraska. Since earning his degree, he has held numerous staff, clinical, and leadership positions in hospital, GPO, and managed care settings.Dr. Ola Gaber is a Medical Oncologist who graduated from the University of Cairo in 2007. She spent her residency and fellowship in University of Cairo Hospitals and earned a master degree in acute leukemias. She moved to USA in 2016 where she worked in Cancer Research. Her research involved using exosomes as biomarker for Cancer patients, Circulating Tumor DNA and TET2 Mutations in Acute Leukemia.Dr. Arnold Waine has completed his post-graduate studies at the University of Papua New Guinea. He finished his undergraduate studies (MBBS) in 2002. Recent past he was attached as a Research Fellow to Auckland University under the New Zealand Pacific scholarship program.
He is the foundation director to James Waine Cancer Institute in Papua New Guinea. A cancer care and research institution in the country. Currently he is a senior lecturer in surgery at the University of Papua New Guinea and an honorary consultant surgeon at Port Moresby General Hospital, Port Moresby, Papua New Guinea. His special interest is in Breast and Liver cancer in Pacific Islanders.Dr. Giulio Tarro graduated from Medicine School, Naples University (1962). Research Associate, Division of Virology and Cancer Research, Children’s Hospital (1965-1968), Assistant Professor of Research Pediatrics, College Medicine (1968-1969), Cincinnati University, Ohio. Oncological Virology Professor, Naples University (1972-1985). Chief Division Virology (1973-2003), Head Department Diagnostic Laboratories, (2003-2006). D. Cotugno Hospital for Infectious Diseases, Naples, Emeritus, 2006 -. Since 2007 Chairman Committee of Biotechnologies and Virus Sphere, World Academy Biomedical Technologies, UNESCO, Adjunct Professor Department Biology, Temple University, College of Science and Technology, Philadelphia, recipient of the Sbarro Health Research Organization lifetime achievement award (2010). President Foundation de Beaumont Bonelli for Cancer Research. His basic researches have been concerned with antigens induced early during the replication cycle of human herpesviruses. Another study has involved the identification, isolation and characterization of specific virus-induced tumour antigens, which were the "finger-prints" left behind in human cancer. Achievements include patents in field, discovery of Respiratory Syncytial Virus in infant deaths in Naples and of tumor liberated protein as a tumor associated antigen, 55 kilodalton protein overexpressed in lung tumors and other epithelial adenocarcinomas.Dr. Roberto Lucio Lazo was graduated at the University of Havana Cuba in medicine in the year 1975, afterwards, in the year 1981 he finished the residence of Oncology in the National Cancer Institute in Havana Cuba. He worked in the service of mastology for one year and afterwards he was translated to the Unit of Oncology of Pinar del Rio from the year 1982 to the present date. In that time he worked for two years in Georgetown, Guyana and two years in Praia, Republic of Cabo Verde. In the Unit of Oncology of Pinar del Rio he worked for more than 15 years as breast cancer surgeon. He worked in all that time as a clinical Oncologist and Radiotherapist too. He was director of the Unit of Oncology of Pinar del Rio from the year 2001 until the year 2013. He has participated in multiples international conferences in Cuba and other countries, including Adjuvant Therapy of primary breast cancer in Switzerland where he presented investigations papers. He has presented publications in different journals in relations with his investigations, where it is very important the discovery of the formula of the waste of cholesterol that put in evidence that there is a misbalance in the human body that can be measured by the formula of the waste of cholesterol, which it is important in the etiology of different cancers including breast cancer. He is member of the editorial Committee of the journal CPQ Cancer. He is auxiliary professor of Oncology at the University of Pinar del Rio. He has been President of the Society of Oncology in Pinar del Rio from the year 1985 until the present and he was member of the Direction of the Cuban Society of Oncology for 4 years from the year 2006-2010. He is actually Auxiliary Professor of Oncology and Specialist of second degree in Oncology.Dr. Divyanshu ‘Divy’ Dua is a consultant medical oncologist and Fellow of the Royal Australasian College of Physicians (RACP). Dr. Dua trained in internal medicine and medical oncology in Australia as part of FRACP before completing a clinical fellowship in drug development, early phase trials and thoracic malignancies at the Guy’s Hospital, London (UK), and the Sarah Cannon Research Institute (UK).
Dr. Dua has published several articles in peer reviewed international journals. He is actively involved in teaching and research through his current affiliation with the Australian National University, Canberra. Past academic affiliations include the University of Adelaide, Flinders University, Monash Rural school of Medicine in Australia and King’s College London. He is also active in training of the Physician training program.
Qualifications:
• Fellow of Royal Australasian College of Physicians (FRACP)
• Fellow of Academy of General Education (FAGE)
Dr. Manar Montasser, 31 years old, has completed her Master degree of Sciences in clinical oncology at the age of 28-year form Suez Canal University. She had worked as a local officer of the standing committee on reproductive health and AIDS including reproductive oncology, then a president of Suez Canal medical students’ association (SCMSA) a member of the international federation of medical students ‘associations (IFMSA). She worked as an assistant lecturer of clinical oncology in Suez Canal University. She has published 3 papers in reputed journals was a speaker in 2 international oncology conferences.Dr. Edem Kwabla Sosu is a trained medical physicist and research scientist with experience in medical imaging particularly mammography. He has competencies in quality control and quality assurance of diagnostic radiology equipment, commissioning and acceptance test of Nuclear Medicine equipment and radiation protection. He holds a PhD in Physics, an MPhil in Medical Physics and a BSc. (Hons) Physics.
Through the efforts of the International Atomic Energy agency (IAEA), Dr. Sosu has received further training over the years improving his competencies and abilities in the field of mammography and medical imaging in general.
Dr. Sosu is currently a Principal Research Scientist and the Manager of the Medical Radiation Physics Centre of the Radiological and Medical Sciences Research Institute, Ghana Atomic Energy Commission where he leads a team of researchers to under research into medical imaging and treatment planning with the aim of improving treatment outcomes of patients. After successfully undertaking Audit of all three Radiotherapy Centre’s in Ghana, the Centre is currently undertaking a similar exercise on all diagnostic radiology facilities in the Country. He is also a Senior lecturer and Thesis supervisor at the Graduate School of Nuclear and Allied Sciences, University of Ghana, Accra. Ghana.Dr. Bhalchandra Mirlekar is an immunologist with a deep and long-lasting interest in how the immune response shapes cancer and autoimmune disease. He is leveraging the immunosuppressive populations that restrain anti-tumor immunity in pancreatic cancer and malignant melanoma, with developing new immune-based therapy options for these deadly malignancies. He acquired the knowledge, training and experience in the field of immunology to effectively carry out research in basic immunology for better translation of research findings to clinical applications. He worked on molecular mechanism of T cell differentiation associated with auto-inflammatory responses. He proposed that the regulatory T cell (Treg) function and cytokine signaling dictates the balance between Treg and Th17 cells. In addition to many first-author publications, he has written several collaborative co-authored peer-reviewed publications in collaboration during my research studies. Currently, he is working on cellular and molecular mechanisms of B cell-mediated immune responses during pancreatic cancer and malignant melanoma initiation and progression.Dr. Christian Ngatali
Work experience
From 2009 to today : medical oncologist,,br>
From 2012 to today : head of oncology department, loandjili general hospital, Pointe Noire, Congo
From 2015 to today : teacher researcher in oncology, health sciences faculty, Marien Ngouabi University of Brazzaville, Congo
Dr. Eben Von Well received his PhD degree in Genetics (main focus: cytogenetics and mutation breeding) in 2005, at the University of Pretoria, South Africa. During the period of 1996-1999 he worked as a practical assistant at the University of Pretoria in the cytogenetics section of the Genetics Department. He work for Genepath, the genetics laboratory of the Ampath pathology group, from 2000-2006. There he specialized in leukaemia cytogenetics analysis. From 2006 until present, he worked as senior researcher in the field of plant mutation breeding and became the curator of the Small Grain Germplasm Collection in 2011. The plant mutation breeding research includes cytogenetic analysis as well as efficiency of energy conversion determination in prediction of the optimal gamma irradiation dosage for mutation breeding. Chromosomal aberrations, NOR activity, G2 check points, cell death, incomplete mitotic divisions are used as indicators for measuring the effect of the gamma irradiation. He has 10 congress contributions and 8 articles in peer reviewed journals. He is also a peer reviewer for an international agricultural journal.Dr. Moueden Mohamed Amine is associate professor and professor researcher in medical school of Oran in Algeria. He had worked four years in the field of blood transfusion, presently he is working in biological hematology department of Oran hospital in Algeria, he taught medical virology at the University of Sidi Bel abbes in Algeria. He participated in many national and international congresses. He has completed numerous trainings in the field of molecular biology, flow cytometry and applied statistics in medicine.Dr. Tesfaye received BSc degree in Ethiopia in 2007. Two years later, he matriculated at JimmaUniversity and received MSc degrees as a Microbiologist Scholar. Also, he was employeed as one of the Lecturer and research staff in Jigjiga and then Wolkite University since 2012. For several years, he has been involved in developing and improving research and teaching and learning systems in Ethiopia Higher education as well as helping hospitals design and implement Laboratory facilities. Tesfaye authored more than 18 scientific research outputs since 2013. Currently he is a research fellow in Tsinghua University and working mainly on Cancer immunotherapy.Dr. Prashanth Kumar Bhusetty Nagesh is a Senior research scientist in the Molecular Pharmacology program at Memorial Sloan Kettering cancer center. Dr. Prashanth did his Ph.D. in Cancer Biology and Nanomedicine from IIT, Kharagpur, India. He has been working on cancer therapeutics, Radiation Biology & Nano drug delivery systems. He is a member of the American Association of cancer research and the American association of pharmaceutical Society. Dr. Prashanth has published >45 peer-reviewed papers in high-impact journals. He is also acting as a peer reviewer for many journals in the fields of oncology, Cell Biology, and Nanotechnology. He has substantial experience in various aspects of cancer therapies. He has successfully completed various projects as a Ph.D. and Postdoctoral Fellow by collaborating with many co-researchers.Dr. Upasna Srivastava holds a Ph.D. degree in Bioinformatics and currently working as a Postdoc Research Scientist in the department of pediatrics, University of California, San Diego, the USA for a human cystic fibrosis microbiome project before this, she worked on a project scientist at the department of cell biology, The Cancer Institute of JFCR, Ariake, Koto, Tokyo, Japan. for two projects first on “Single-cell analysis of colon cancer omics data” and the second was “Mechanism of Metastasis and Recurrence in Colon cancer organoids” also she had research experience as a postdoctoral researcher from the University of Tokyo, Japan for single-cell analysis of Cancer tissues projects, and collaboration projects on “child single-cell neuroblastoma and cancer epigenomics”.
Interests
Cancer, Radiation Therapy, Cytoskeletal Crosslinking, Brain Tumors and Biological Sciences.Surgical Science, Biological Sciences, Molecular mechanism, Neoplasms and Developmental Biochemistry.Uncovering the Mechanisms of Innate Immunity in Metastasis.Hepatobiliary and Pancreatic diseasesEnvironmental Carcinogens, Prediction, Early Diagnosis and Prevention.Medical Biotechnology, Molecular Medicine, Medical Biotechnology and Molecular Oncology.Cancer, Tumors of Lung, Thymus, Esophagus, Chemotherapy and Immunotherapy.Pharmaceutical Research, Pharmaceutics, Pharmacology, Pharmaceutical Biotechnology, Pharmaceutical Nanotechnology, Toxicology, Cancer Therapy, Cancer Chemotherapy and Pharmacology. Oncology and Radiotherapy.Diabetes and CancerCancer Research, Drug Design and Discovery, Natural Products and Biochemistry Sciences.Dr. Rahmati’s research interests are mainly focused on the development of therapeutic nanoparticles and involvement of apoptosis/autophagy and ER stress pathways in cancer drug resistance.
His research interests include Signal Transduction, Protein and RNA modification.Head and Neck Cancer, Oral Cancer, Oropharyngeal Cancer, Tobacco, Alcohol, HPV, Oral Health, Cancer prevention and screening.Dr. Susanna Akiki’s work focuses on the rapid translation of genomic research into clinical practise, integrating services across the laboratory, clinic and academia. She has published consistently throughout her career and holds academic positions in both Qatar & the UK. Dr Akiki is a member of the Science & Publications committee of the British Society of Haematology and helps to promote standardised best practise in haematology.Health, Toxicity, Occupational Genotoxicity and Immunology.Breast Cancer, Brain Cancer, Skin cancer, Human, Animal genetics. Protein Modifications, Ubiquitination, Oxidation, Signaling, Trafficking, Drug discovery,
Proteomics.
Cancer Genetics and Tumor Biology. Forensic Medicine, Bioethics, Embryology and Genetics.Breast Cancer, Chemotherapy in Gynaecological Malignancies, Cervical Cancer.Malignant Pediatric Brain Tumors and Immunotherapy. Breast, ovarian and colorectal cancer, Cancer Genetics and Genetic Counseling.Cancer Surgery and Oncology.Toxicity assessments of environmental chemicals and anticancer drug with special emphasis on cytotoxicity, oxidative stress mediated DNA damages, protein expression of inflammatory and apoptotic marker genes involved in cell death,
Anticancer and antioxidant activities of various dietary supplements.Hematological Malignancies, Hematologic Diseases, Hematopoietic Stem Cell Transplantation, Immunophenotyping, Hemoglobinopathies, Flow Cytometry, Bone Marrow Diseases, Bone Marrow Examination, Transplantation Conditioning, Cord Blood Stem Cell, Molecular Haematology, Hematopoietic Stem Cell Mobilization ,Transfusion Medicine.His areas of research interest are: Lung Cancer, Pleural Diseases, Sarcoidosis, ?nterstitial Lung Diseases, Fiberoptic Bronchoscopy and Medical Thoracoscopy.Cancer Cells, Endothelial Cells, Tumor Metastasis.The major research interest of Dr. El-Senduny is cancer biology, anti-metastasis, anti-invasion, drug discovery and natural products as alternative therapy.Dr. Raquel Santana da Cruz research career has acquired a strong background in multiple Biological and Nutritional Disciplines including Molecular Biology, Nutrition and Cancer prevention and Breast Cancer/Translational Research.Oncology and RheumatologyHer research involved using Exosomes as Biomarker for Cancer patients, Circulating Tumor DNA and TET2 Mutations in Acute Leukemia.Breast and Liver Cancer.His basic researches have been concerned with antigens induced early during the replication cycle of human herpesviruses. Another study has involved the identification, isolation and characterization of specific virus-induced tumour antigens, which were the “finger-prints” left behind in human cancer. Achievements include patents in field; discovery of Respiratory Syncytial Virus in infant deaths in Naples and of tumor liberated protein as a tumor associated antigen, 55 kilodalton protein overexpressed in lung tumors and other epithelial adenocarcinomas.Breast Cancer, Oncology1. Thoracic Malignancies including lung cancers, mesothelioma and thymoma
2. Genitourinary Malignancies
3. Metastatic Melanoma
4. CNS tumours
5. Sarcoma
6. Drug development and early phase clinical trialsHer research interests are clinical oncology, being medical and radiation oncology, especially in breast cancer and gynecological cancers.Mammography, Medical Radiation Physics• Tumor immunology
• Cancer immunotherapy: Drug discovery, clinical trials, studies on cancer patient samples
• Molecular mechanism behind generation of innate and adaptive immune responses
• Immune cell and cytokine signaling
• Generation of transgenic, gene knock-out, cancer and autoimmune animal models
• Flow cytometry based research
Clinical, Medical, Specially in Cancer Research AreaLeukaemia, Cytogenetics, Chromosomal Aberrations, NOR Activity, G2 Check Points, Cell Death, Incomplete Mitotic Division, Efficiency of Energy Conversion.Malignant Hemopathies, Cytology, Flow Cytometry and HemostasisCancer Immunotherapeutics and BacteriotherapyDr. Prashanth’s research interests include Cancer biomarkers and Therapeutics, Cancer Immunology, Molecular bioimaging, Radiation therapies, Nanomedicine, drug screening for anti-cancer activity, Chemoresistance, antibody development, and medical radiation countermeasures.Dr. Upasna Srivastava’s research interests include Microbiome diversity analysis, Cancer Organoids, neuroblastoma single-cell analysis, single-cell Time series analysis, ATAC seq-data analysis, gene set enrichment, miRNA and microarray data analysis, single-cell epigenetics analysis, GWAS, eQTL analysis, Epigenomics analysis, machine learning approaches in cancer and microbiome.
+1 249-493-6904
